secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2025-06-06T23:59:59+00:00
Accession:  0000950170-25-082705
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel appoints Maha Radhakrishnan, M.D., to Board; BLA submission for CAN-2409 on track for Q4 2026
--------------------------------------------------------------------------------

- Board expanded from 9 to 10 directors; Radhakrishnan named to Class II, term expiring 2026.
- Appointment effective June 4, 2025; she receives option for 28,480 shares vesting over 3 years.
- Radhakrishnan previously Group SVP and Chief Medical Officer at Biogen (Jan 2020 – Mar 2024).
- Candel targets Q4 2026 Biologics License Application submission for CAN-2409 in prostate cancer.
- She also serves as Executive Partner at Sofinnova Investments since August 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017025082705/0000950170-25-082705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017025082705/cadl-20250604.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-082705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer